Cleveland Clinic Abu Dhabi: A New Era of Cardiac Excellence

By HEOR Staff Writer

November 5, 2023

A Landmark Achievement in Healthcare

The Department of Health – Abu Dhabi (DoH) has declared Cleveland Clinic Abu Dhabi, a component of the M42 network, as a Centre of Excellence (CoE) for Adult Cardiac Surgery (ACS). This significant announcement is a testament to Abu Dhabi’s commitment to delivering world-class healthcare services to its community and reinforces its standing as a leading healthcare destination.

Centre of Excellence for Adult Cardiac Surgery: A New Standard in Cardiac Care

As an ACS CoE, Cleveland Clinic Abu Dhabi offers a comprehensive range of cardiac surgery and structural heart disease interventions. These services are provided by a team of highly experienced cardiologists and some of the world’s most reputable surgeons. The Clinic boasts dedicated cardiac surgery ICU facilities and cardiac operating rooms, supported by core services that include multidisciplinary cardiovascular medicine, interventional cardiology, electrophysiology, and a pioneering structural heart programme.

H.E. Dr. Noura Al Ghaithi, Undersecretary of the DoH, emphasised the importance of the CoE programme in elevating healthcare outcomes and increasing competitiveness across the sector. She expressed delight at the announcement and looked forward to the continuous contributions from partners to enhance the healthcare sector’s excellence.

Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi and Managing Director and Group Chief Executive Officer of M42, highlighted the Clinic’s establishment as a regional and global benchmark for complex care. He reiterated their commitment to excellence and the vision of providing world-class complex care to patients in the UAE and across the region.

Reference url

Recent Posts

Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU

By João L. Carapinha

March 4, 2026

EMA's Push for Microbiome Medicinal Products Guidance EMA's Non-Clinical Working Party has drafted a concept paper, adopted by CHMP on 16 February 2026, proposing a reflection paper to guide non-clinical development of microbiome...
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

By João L. Carapinha

March 3, 2026

Tirzepatide Cost Effectiveness in UK T2D Care Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
CHMP February 2026 Approvals: 12 New Medicines and Biosimilars Advance The CHMP Febru...